Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab versus Ranibizumab + Verteporfin PDT in neovascular AMD
2006-006760-28Phase 3Completed
- Sponsor
- Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie
- Start
- May 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ranibizumab and verteporfin in exudative macular degeneration (2 arms), sponsored by Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie. Primary endpoint: Best corrected visual acuity stability between month 2 and month 12. Started May 2007; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2006-006760-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006760-28.